Balavoine et al, “Prostaglandin E2 and Collagenase Production by Fibroblasts and Synovial Cells Is Regulated by Urine-Derived Human Interleukin 1 and Inhibitors(s)”, J. Clin Invest 78:1120-1124 (1986). |
Beutler et al, “Passive Immunization against Cachectin/Tumor Necrosis Factor Protects Mice from Lethal Effect of Endotoxin”, Science 229:869-871 (1985). |
Beutler et al, “Cachectin: More than a Tumor Necrosis Factor”, New Eng J Med 316(7):379-385 (1987). |
Beutler et al, Tumor Necrosis Factors . . . , Raven Press, New York, pp. 145, 383 (1992). |
Bigda et al, “Dual Role of the p75 Tumor Necrosis Factor (TNF) Receptor in TNF Cytotoxicity”, J Exp Med 180:445-460 (1994). |
Brockhaus et al, “Monoclonal Antibodies against the TNF-Receptor Inhibit . . . ”, 2nd Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan. 15-20, 1989, p. 140. |
Brockhaus et al, “Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies”, Proc Natl Acad Sci U S A 87(8):3127-3131 (1990). |
Chen et al, “Mapping the domain(s) critical for the binding of human tumor necrosis factor-alpha to its two receptors”, J Biol Chem 270(6):2874-2878 (1995) (Abstract). |
Creasey et al, “Biological Effects of Recombinant Human Tumor Necrosis Factor and Its Novel Muteins on Tumor and Normal Cell Lines”, Cancer Research 47:145-149 (1987). |
Engelmann et al, “Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine”, J Biol Chem 265(3):1531-1536 91990). |
Harris et al, “Therapeutic antibodies—the coming of age”, TIBTECH 11:42-44. (1993). |
Higuchi et al, “Modulation of two forms of tumor necrosis factor receptors and their cellular response by soluble receptors and their monoclonal antibodies”, J Biol Chem 267(29):20892-20899 (1992). |
Hohmann et al, “Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)”, J Biol Chem 264(251)14927-14934 (1989). |
Hohmann et al, “Two Different Cell Types Have Different Major Receptors for Human Tumor Necrosis Factor (TNFalpha)”, 2nd Int'l Conf. Tumor Necrosis Factor and Related Cytokines, Jan. 15-20, 1989, p. 143. |
Loetscher et al, “Purification and partial amino acid sequence analysis of two distinct tumor necrosis factor receptors from HL60 cells”, J Biol Chem. 265(33):20131-20138 (1990). |
Natanson et al, “Selected Treatment Strategies for Septic Shock Based on Proposed Mechanisms of Pathogenesis”, Annals of Int Med 120(9):771-783 (1994). |
Parrillo Je, “Pathogenetic Mechanisms of Septic Shock”, New Eng J Med 328(20):1471-1477 (1993). |
Peetre et al, “A tumor necrosis factor binding protein is present in human biological fluids”, Eur J Haematol 41:414-419 (1988). |
Schall et al, “Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor”, Cell 61:361-370 (1990). |
Seckinger et al, “A Human Inhibitor of Tumor Necrosis Factor alpha”, J Exp Med 167:1511-1516 (1988). |
Smith et al, “A Receptor for Tumor Necrosis Factor Defines an Unusual Family of Cellular and Viral Proteins”, Science 248:1019-1023 (1990). |
Stauber et al, “Human Tumor Necrosis Factor-alpha Receptor”, J Biol Chem 263(35):19098-19104 (1986). |
Tracey et al, “Shock and Tissue Injury Induced by Recombinant Human Cachectin”, Science 234:470-474 (1986). |
Tracey et al, “Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia” Nature 330:662-664 (1987). |
Unglaub et al, “Downregulation of Tumor Necrosis Factor (TNF) Sensitivity Via Modulation of TNF Binding Capacity by Protein Kinase C Activators”, J Exp Med 166:1788-1797 (1987). |
Wallach D, “Cytotoxins (Tumor Necrosis Factor, Lymphotoxin and Others); Molecular Functional Characteristics and interactions with interferons”, Interferon 7:90-124 (1986). |
Weir (Ed.), Handbook of Experimental Immunology, vol. 1, Blackwell Scientific Publications; Oxford, pp. 8.14-8.15. |
Whitlow et al, “Single-Chain Fv Proteins and Their Fusion Proteins,” Methods 2(2):97-105 (1991). |